Therapeutic and research uses of tooth-derived stem cells (TSC)
Columbia University Science & Technology Ventures
07/06/2009
http://www.ibridgenetwork.org/columbia/ir2293-2524-mao
Problem or Unmet Need
Considering the ethical concerns over the use of embryonic stem cells, alternative stem cell sources are necessary for regenerative therapies.
Companies have recently formed to bank cells from these alternative sources, ready to be used in the future when stem cell therapies become clinically available. Such companies include several in the business of tooth banking, including StemSave, Store-a-Tooth, BioEden, CryoTooth, some of whom have expanded their services into Europe, Asia, and the Middle East.
Stem cells derived from deciduous (baby) teeth and adult teeth have been isolated and a number of studies have shown these cells to be multipotent. Specifically, studies have shown that these Tooth-derived Stem Cells (TSCs) can be differentiated into osteoblasts, neuron-like cells, and adipocytes.
The present invention demonstrates that TSCs can be differentiated into additional cell types, including pancreatic beta cells, myogenic cells, chondrogenic cells, hair follicle cells and embryonic stem cell-like cells. These cells or the protein products thereof can be applied in the treatment of diabetes, muscular dystrophy, arthritis, augmentative and reconstructive surgeries, and alopecia.
Details of the Invention
This technology consists of a method of isolating TSCs from the inner soft tissue of deciduous teeth, and methods for differentiating TSCs into the following cell types:
• TSC-derived pancreatic islet beta cells capable of producing high levels of insulin; data shows these cells express the beta cell transcription factor PDX1 and stain positive for C-peptide (a byproduct after processing of pro-insulin).
• TSC-derived chondrocytic cells capable of synthesizing the extracellular glucosaminoglycans; data show these cells stain positive for safranin-O (insert function).
• TSC-derived hair follicle cells capable of producing dermal papilla cells and outer root sheath cells; data show these cells express Lef1 transcription factor and are CD59 positive, respectively.
• TSC-derived myogenic cells which express MyoD (a transcription factor expressed in native myoblasts) and desmin (a myocyte structural protein).
• TSC-derived embryonic stem cell-like cells which express many of the markers of embryonic stem cells, including Oct3/4, SSEA4 and Nanog.
Suggested Uses
• Cells can be used to create patient-specific and/or disease-specific assays for basic research, drug-screening and drug-testing purposes
• TSC-derived pancreatic islet beta cells can be used in autologous transplantation therapy for type I diabetes
• TSC-derived chondrocytic cells can be used in regenerative therapies to restore the damaged cartilage tissue caused by osteoarthritis, trauma or primary orthopedic disorders
• TSC-derived hair follicle cells can be used in the treatment of hair loss (alopecia) of diverse origins
• TSC-derived myoblasts can be used in regenerative therapies for myopathies (drug and toxin-induced, metabolic, endocrinologic) and muscular dystrophies
Advantages
• TSCs are easily accessible after procedural tooth extractions, without any genetic manipulation or ethical conflicts
• TSCs have multiple differentiation potential, which could be adapted in wide range of therapies
• Autologous TSCs can be derived for regenerative therapy; the risk of adverse immunological reactions after transplantation could be minimized
• TSCs have higher proliferation rates compared with other stem cells from other sources, such as bone-marrow-derived mesenchymal stem cells and adipose-derived stem cells, allowing for relatively faster and easier tissue amplification
Innovation Details
Lead Inventors: Jeremy J. Mao Ph.D.
http://bme.columbia.edu/fac-bios/mao/faculty.html
Jeremy J. Mao
Professor of Dental Medicine
PH7 East
630 West 168th Street
Phone: +1 212-305-9393
Email: jmao@columbia.edu
Home Page
Detailed Description
Patent Status: Patent Pending
Licensing Status: Available for Licensing and Sponsored Research Support
Publications: N Y State Dent J. 2008 Mar;74(2):20-4
Further Information: Science and Technology Ventures, Columbia University
Donna See, Tel: (212) 305-7214
Email: TechTransfer@columbia.edu
File Number: IR 2293 / 2524
Web site: http://www.ncbi.nlm.nih.gov/pubmed/18450184?ord...
IP Protection
Patent Information: A non-provisional patent application has been filed.
License Online
This innovation currently is not available for online licensing. Please contact Brendan Rauw at Columbia University Science & Technology Ventures for more information
Columbia University Science & Technology Ventures
07/06/2009
http://www.ibridgenetwork.org/columbia/ir2293-2524-mao
Problem or Unmet Need
Considering the ethical concerns over the use of embryonic stem cells, alternative stem cell sources are necessary for regenerative therapies.
Companies have recently formed to bank cells from these alternative sources, ready to be used in the future when stem cell therapies become clinically available. Such companies include several in the business of tooth banking, including StemSave, Store-a-Tooth, BioEden, CryoTooth, some of whom have expanded their services into Europe, Asia, and the Middle East.
Stem cells derived from deciduous (baby) teeth and adult teeth have been isolated and a number of studies have shown these cells to be multipotent. Specifically, studies have shown that these Tooth-derived Stem Cells (TSCs) can be differentiated into osteoblasts, neuron-like cells, and adipocytes.
The present invention demonstrates that TSCs can be differentiated into additional cell types, including pancreatic beta cells, myogenic cells, chondrogenic cells, hair follicle cells and embryonic stem cell-like cells. These cells or the protein products thereof can be applied in the treatment of diabetes, muscular dystrophy, arthritis, augmentative and reconstructive surgeries, and alopecia.
Details of the Invention
This technology consists of a method of isolating TSCs from the inner soft tissue of deciduous teeth, and methods for differentiating TSCs into the following cell types:
• TSC-derived pancreatic islet beta cells capable of producing high levels of insulin; data shows these cells express the beta cell transcription factor PDX1 and stain positive for C-peptide (a byproduct after processing of pro-insulin).
• TSC-derived chondrocytic cells capable of synthesizing the extracellular glucosaminoglycans; data show these cells stain positive for safranin-O (insert function).
• TSC-derived hair follicle cells capable of producing dermal papilla cells and outer root sheath cells; data show these cells express Lef1 transcription factor and are CD59 positive, respectively.
• TSC-derived myogenic cells which express MyoD (a transcription factor expressed in native myoblasts) and desmin (a myocyte structural protein).
• TSC-derived embryonic stem cell-like cells which express many of the markers of embryonic stem cells, including Oct3/4, SSEA4 and Nanog.
Suggested Uses
• Cells can be used to create patient-specific and/or disease-specific assays for basic research, drug-screening and drug-testing purposes
• TSC-derived pancreatic islet beta cells can be used in autologous transplantation therapy for type I diabetes
• TSC-derived chondrocytic cells can be used in regenerative therapies to restore the damaged cartilage tissue caused by osteoarthritis, trauma or primary orthopedic disorders
• TSC-derived hair follicle cells can be used in the treatment of hair loss (alopecia) of diverse origins
• TSC-derived myoblasts can be used in regenerative therapies for myopathies (drug and toxin-induced, metabolic, endocrinologic) and muscular dystrophies
Advantages
• TSCs are easily accessible after procedural tooth extractions, without any genetic manipulation or ethical conflicts
• TSCs have multiple differentiation potential, which could be adapted in wide range of therapies
• Autologous TSCs can be derived for regenerative therapy; the risk of adverse immunological reactions after transplantation could be minimized
• TSCs have higher proliferation rates compared with other stem cells from other sources, such as bone-marrow-derived mesenchymal stem cells and adipose-derived stem cells, allowing for relatively faster and easier tissue amplification
Innovation Details
Lead Inventors: Jeremy J. Mao Ph.D.
http://bme.columbia.edu/fac-bios/mao/faculty.html
Jeremy J. Mao
Professor of Dental Medicine
PH7 East
630 West 168th Street
Phone: +1 212-305-9393
Email: jmao@columbia.edu
Home Page
Detailed Description
Patent Status: Patent Pending
Licensing Status: Available for Licensing and Sponsored Research Support
Publications: N Y State Dent J. 2008 Mar;74(2):20-4
Further Information: Science and Technology Ventures, Columbia University
Donna See, Tel: (212) 305-7214
Email: TechTransfer@columbia.edu
File Number: IR 2293 / 2524
Web site: http://www.ncbi.nlm.nih.gov/pubmed/18450184?ord...
IP Protection
Patent Information: A non-provisional patent application has been filed.
License Online
This innovation currently is not available for online licensing. Please contact Brendan Rauw at Columbia University Science & Technology Ventures for more information
